Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs. Issue 3 (15th January 2019) - Virani, Salim S.; Akeroyd, Julia M.; Nambi, Vijay; Michos, Erin D.; Morris, Pamela B.; Nasir, Khurram; Smith, Sidney C.; Stone, Neil J.; Petersen, Laura A.; Ballantyne, Christie M.